Earnings season has just finished, the economy is growing slowly (but also too quickly!), and rate rises are on the horizon.

There is a lot going on in the world at the moment. And it’s affecting our economy and investments.

Our Chief Investment Officer, Scott Phillips, will be hosting a LIVE one-hour market update and Q&A TODAY, September 4, 2026 at 12pm AEST to update viewers with his thoughts on all of that and more.

Plus, taking your questions, LIVE, on YouTube in the process.

And you can watch it right here!

The post YouTube LIVE: Today at 12pm AEST appeared first on The Motley Fool Australia.

More reading

• WIN Group increases Nine Entertainment stake past 31%
• Stanmore Resources to acquire Moranbah South, boosting coal resources
• Could this ASX healthcare stock really be set to rise 400%? Morgans thinks so 
• Up 83%! 4 reasons I’d still buy this $8 billion ASX 200 gold stock today
• If I buy $4,000 of Wesfarmers shares, how much dividend income will I receive?

Motley Fool contributor Scott Phillips has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Stanmore Resources Ltd (ASX: SMR) share price is in the spotlight after the company announced a $105 million deal to acquire 100% of the Moranbah South coal tenements, boosting its resource base with 724 million tonnes of measured and indicated coal.

What did Stanmore Resources report?

• Stanmore agreed to acquire all of Moranbah South from Exxaro for US$105 million.
• The Moranbah South tenements contain 724 million tonnes of measured and indicated coal resources.
• The deal is conditional on Exxaro acquiring Anglo American’s 50% joint venture stake, giving Exxaro full ownership ahead of sale to Stanmore.
• The acquisition removes up to US$60 million in deferred and contingent payments for Stanmore’s Isaac Downs Extension project.
• Stanmore will fund the acquisition from existing cash and liquidity, so no shareholder approval is required.

What else do investors need to know?

The Moranbah South tenements are strategically located next to Stanmore’s existing Eagle Downs and Isaac Plains Complex mines in Queensland’s Bowen Basin. The resources are considered to be high-quality, premium hard coking coal and may benefit from shared infrastructure if Eagle Downs is developed.

This transaction is expected to add significant value across Stanmore’s portfolio by increasing resource scale and potentially lowering development costs. The deal also cancels significant future payment obligations tied to earlier agreements on the Isaac Downs Extension, making the economics more attractive.

Completion is expected before the end of 2026, subject to Exxaro acquiring full ownership and meeting regulatory approvals including the Foreign Investment Review Board and ACCC. An independent resource report is planned after the deal closes.

What did Stanmore Resources management say?

Chief Executive Officer & Executive Director Marcelo Matos said:

The acquisition of the Moranbah South tenements will represent a significant milestone for Stanmore’s development portfolio, increasing our resource base and strengthening the platform to deliver on our future growth aspirations. The tenements are strategically complementary to Stanmore’s neighbouring projects, particularly Eagle Downs and the Isaac Downs Extension.

What’s next for Stanmore Resources?

Stanmore has signalled its intent to commission an independent report on the newly acquired resources, aiming to update shareholders and the market once new technical and feasibility studies are complete. If the acquisition closes as planned, Moranbah South could provide long-term synergies to future mining operations and development options.

The company remains focused on strategic growth from its expanded portfolio and delivering increased value for investors as integration and further exploration proceeds.

Stanmore Resources share price snapshot

Over the past 12 months, Stanmore Resources shares have risen 64%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Stanmore Resources to acquire Moranbah South, boosting coal resources appeared first on The Motley Fool Australia.

More reading

• Stanmore Resources posts higher revenue and steady production in 1H FY26

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

ASX healthcare stock Saluda Medical Inc (ASX: SLD) has been drawing significant attention from brokers in recent weeks. 

The growth stock is a commercial-stage medical device company. It is focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. 

The company’s first product, the Evoke System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy.

It hasn’t been smooth sailing for this ASX healthcare stock in recent times. Its share price has tumbled 71% year to date. 

However, Morgans sees major upside over the next 12 months. 

Here’s the latest from the broker. 

Solid FY26 for ASX healthcare stock

In a note out of Morgans this week, the broker said FY26 finished strong and mostly ahead of prospectus, but the more important development is showing greater visibility on the path to operating leverage. 

FY27 guidance calls for 25% to 35% revenue growth, 50% to 52% gross margin, and a US$95 to $101 million adjusted EBITDA loss, with management expecting 90% of incremental gross profit to translate into adjusted EBITDA improvement. 

Salesforce maturation is key, with 161 US reps at FY26 year-end, 55% fully trained and the majority of the remaining cohort expected to come online in 1HFY27. Growth looks set to come from higher productivity rather than simply adding headcount, with c30% of territories operating below a 40% fully loaded rep-cost/revenue threshold, providing evidence that the territory economics can work. 

We see FY27 as the first meaningful test of the model’s scalability, with higher physician utilisation, maturing territories and the CAP24 paddle lead providing potential upside to guidance. We adjust FY27-28 forecasts, with our DCF-based target price moving to A$2.17 (from A$2.94). SPECULATIVE BUY maintained.

This ASX healthcare stock closed trading yesterday at just over 41 cents per share. 

The target from Morgans indicates an upside potential of 422%. 

Other brokers also bullish

Morgans isn’t alone in its outlook for this ASX healthcare stock. 

The team at Bell Potter recently updated their price target to $1.60. 

This indicates an upside of over 285%. 

Speaking on the lofty target, the broker said: 

SLD’s US commercial execution continues to impress and accelerated considerably in recent quarters (34% US growth in Q3, 45% in Q4). Tailwinds continue to build following FDA approval of SLD’s paddle lead in June and ~40% of the current sales force expected to complete training in FY27 and contribute to revenue generation. Real-world data continues to affirm Evoke’s value proposition: greater efficacy durability means fewer reprogramming requirements and therefore greater revenue/rep compared to conventional devices.

The post Could this ASX healthcare stock really be set to rise 400%? Morgans thinks so  appeared first on The Motley Fool Australia.

More reading

• Bell Potter says this ASX healthcare share could rise 200%+

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.